Efficacy of oral losartan in recessive dystrophic epidermolysis bullosa.

Authors

  • S. Jangid Department of Dermatology, Datta Meghe Institute of Higher Education and Research
  • B. Madke Department of Dermatology, Datta Meghe Institute of Higher Education and Research
  • V. Saoji Department of Dermatology, Datta Meghe Institute of Higher Education and Research
  • A.L. Singh Department of Dermatology, Datta Meghe Institute of Higher Education and Research

DOI:

https://doi.org/10.26326/2281-9649.35.1.2706

Keywords:

epidermolysis bullosa, losartan, newborn

Abstract

Dystrophic epidermolysis bullosa is caused by a variation in the COL7A1 gene, which encodes type VII collagen. The severity of the disease depends on the type of genetic variant and the domain of the affected protein. We present the case of a 7-day-old infant with recessive dystrophic epidermolysis bullosa, who was treated with oral losartan and showed significant improvement.

Downloads

Published

2025-02-09

How to Cite

Jangid, S., Madke, B., Saoji, V., & Singh, A. (2025). Efficacy of oral losartan in recessive dystrophic epidermolysis bullosa. European Journal of Pediatric Dermatology, 35(1), 34–7. https://doi.org/10.26326/2281-9649.35.1.2706

Issue

Vol. 35 No. 1 (2025)

Section

Original articles